JP2022513029A5 - - Google Patents
Info
- Publication number
- JP2022513029A5 JP2022513029A5 JP2021526256A JP2021526256A JP2022513029A5 JP 2022513029 A5 JP2022513029 A5 JP 2022513029A5 JP 2021526256 A JP2021526256 A JP 2021526256A JP 2021526256 A JP2021526256 A JP 2021526256A JP 2022513029 A5 JP2022513029 A5 JP 2022513029A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inhibitor
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024102591A JP2024123216A (ja) | 2018-11-14 | 2024-06-26 | 皮膚がんを治療するためのｐｄ－１阻害剤の病変内投与 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767218P | 2018-11-14 | 2018-11-14 | |
| US62/767,218 | 2018-11-14 | ||
| PCT/US2019/061212 WO2020102375A1 (en) | 2018-11-14 | 2019-11-13 | Intralesional administration of pd-1 inhibitors for treating skin cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102591A Division JP2024123216A (ja) | 2018-11-14 | 2024-06-26 | 皮膚がんを治療するためのｐｄ－１阻害剤の病変内投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513029A JP2022513029A (ja) | 2022-02-07 |
| JP2022513029A5 true JP2022513029A5 (https=) | 2022-11-07 |
| JP7513604B2 JP7513604B2 (ja) | 2024-07-09 |
Family
ID=68841191
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526256A Active JP7513604B2 (ja) | 2018-11-14 | 2019-11-13 | 皮膚がんを治療するためのｐｄ－１阻害剤の病変内投与 |
| JP2024102591A Pending JP2024123216A (ja) | 2018-11-14 | 2024-06-26 | 皮膚がんを治療するためのｐｄ－１阻害剤の病変内投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102591A Pending JP2024123216A (ja) | 2018-11-14 | 2024-06-26 | 皮膚がんを治療するためのｐｄ－１阻害剤の病変内投与 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12473364B2 (https=) |
| EP (2) | EP4382168A3 (https=) |
| JP (2) | JP7513604B2 (https=) |
| CN (1) | CN113038939A (https=) |
| DK (1) | DK3880186T3 (https=) |
| ES (1) | ES2980363T3 (https=) |
| FI (1) | FI3880186T3 (https=) |
| HR (1) | HRP20240825T1 (https=) |
| HU (1) | HUE067601T2 (https=) |
| LT (1) | LT3880186T (https=) |
| PL (1) | PL3880186T3 (https=) |
| PT (1) | PT3880186T (https=) |
| RS (1) | RS65627B1 (https=) |
| SI (1) | SI3880186T1 (https=) |
| SM (1) | SMT202400252T1 (https=) |
| WO (1) | WO2020102375A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| LT3394103T (lt) | 2015-12-22 | 2023-09-11 | Regeneron Pharmaceuticals, Inc. | Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti |
| EP4313123A1 (en) * | 2021-03-23 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2195342A1 (en) | 2007-09-07 | 2010-06-16 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| EP2825036B1 (en) | 2012-03-16 | 2018-05-02 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified rodents for generating the same |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| RU2689760C2 (ru) | 2012-05-31 | 2019-05-30 | Дженентек, Инк. | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| KR102476226B1 (ko) | 2014-08-05 | 2022-12-12 | 아폴로믹스 인코포레이티드 | 항-pd-l1 항체 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| JP6295998B2 (ja) | 2015-05-12 | 2018-03-20 | 株式会社デンソー | 内燃機関の再始動制御装置 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| LT3394103T (lt) | 2015-12-22 | 2023-09-11 | Regeneron Pharmaceuticals, Inc. | Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti |
| KR20180108655A (ko) | 2016-01-15 | 2018-10-04 | 알에프이엠비 홀딩스, 엘엘씨 | 암의 면역학적 치료 |
| SG11201808626WA (en) | 2016-04-07 | 2018-10-30 | Chemocentryx Inc | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
| TWI910495B (zh) | 2016-05-13 | 2026-01-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| DK3551660T5 (da) | 2016-12-07 | 2024-09-02 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| MA47604A (fr) | 2017-02-21 | 2020-01-01 | Regeneron Pharma | Anticorps anti-pd-1 pour le traitement du cancer du poumon |
| US10166290B2 (en) | 2017-02-24 | 2019-01-01 | Max H. Cohen | Intralesional (Intratumoral) dinitrochlorobenzene and associated compounds coadministered with checkpoint inhibitors for cancer treatment including treatment of metastatic cutaneous cancers |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| CN111201035A (zh) | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
-
2019
- 2019-11-13 SI SI201930759T patent/SI3880186T1/sl unknown
- 2019-11-13 US US17/292,179 patent/US12473364B2/en active Active
- 2019-11-13 SM SM20240252T patent/SMT202400252T1/it unknown
- 2019-11-13 FI FIEP19817846.9T patent/FI3880186T3/fi active
- 2019-11-13 WO PCT/US2019/061212 patent/WO2020102375A1/en not_active Ceased
- 2019-11-13 EP EP24158793.0A patent/EP4382168A3/en active Pending
- 2019-11-13 PL PL19817846.9T patent/PL3880186T3/pl unknown
- 2019-11-13 EP EP19817846.9A patent/EP3880186B1/en active Active
- 2019-11-13 RS RS20240682A patent/RS65627B1/sr unknown
- 2019-11-13 JP JP2021526256A patent/JP7513604B2/ja active Active
- 2019-11-13 PT PT198178469T patent/PT3880186T/pt unknown
- 2019-11-13 DK DK19817846.9T patent/DK3880186T3/da active
- 2019-11-13 CN CN201980074748.7A patent/CN113038939A/zh active Pending
- 2019-11-13 ES ES19817846T patent/ES2980363T3/es active Active
- 2019-11-13 LT LTEPPCT/US2019/061212T patent/LT3880186T/lt unknown
- 2019-11-13 HU HUE19817846A patent/HUE067601T2/hu unknown
- 2019-11-13 HR HRP20240825TT patent/HRP20240825T1/hr unknown
-
2024
- 2024-06-26 JP JP2024102591A patent/JP2024123216A/ja active Pending
-
2025
- 2025-10-24 US US19/368,062 patent/US20260042841A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5823874B2 (ja) | 抗ＣＤ３０ｖｃ−ＰＡＢ−ＭＭＡＥ抗体−薬物コンジュゲートのウィークリー投与計画 | |
| JP2019515008A5 (https=) | ||
| CN111065411A (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2020508317A5 (https=) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| WO2018223923A1 (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2021528423A5 (https=) | ||
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| HK1213782A1 (zh) | 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物 | |
| JP2015500822A5 (https=) | ||
| JP2022513029A5 (https=) | ||
| IL278400B2 (en) | Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer | |
| JP2024534602A5 (https=) | ||
| JP2024527607A5 (https=) | ||
| JP2023520771A5 (https=) | ||
| FI3880186T3 (fi) | PD-1-inhibiittoreiden intralesionaalinen antaminen ihosyövän hoitamiseksi | |
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2025509567A5 (https=) | ||
| JP2023507795A5 (https=) | ||
| JP7159007B2 (ja) | 脳腫瘍の治療のための医薬 | |
| CN111166878A (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| RU2020133811A (ru) | Фармацевтические комбинации | |
| JP2023500480A5 (https=) | ||
| JP2021518348A5 (https=) | ||
| JP2022530599A5 (https=) |